BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
65.97
-0.64 (-0.96%)
At close: Sep 29, 2026, 4:00 PM EDT
66.23
+0.26 (0.39%)
Pre-market: Sep 30, 2026, 4:00 AM EDT
BridgeBio Pharma Market Cap
BridgeBio Pharma has a market cap or net worth of $12.9 billion as of September 29, 2026. Its market cap has increased by 34.79% in one year.
Market Cap
12.90B
Enterprise Value
15.55B
1-Year Change
34.79%
Ranking
Category
Stock Price
$65.97
ChartMarket Cap Chart
Since June 27, 2019, BridgeBio Pharma's market cap has increased from $3.32B to $12.90B, an increase of 288.48%. That is a compound annual growth rate of 20.54%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 29, 2026 | 12.90B | -12.51% |
| Dec 31, 2025 | 14.74B | 184.24% |
| Dec 31, 2024 | 5.19B | -26.16% |
| Dec 29, 2023 | 7.02B | 516.56% |
| Dec 30, 2022 | 1.14B | -53.61% |
| Dec 31, 2021 | 2.46B | -71.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 27, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Jazz Pharmaceuticals | 15.08B |
| Ascendis Pharma | 14.98B |
| Exelixis | 14.53B |
| Summit Therapeutics | 13.08B |
| Halozyme Therapeutics | 12.66B |
| Corcept Therapeutics | 12.40B |
| Madrigal Pharmaceuticals | 11.77B |
| Twist Bioscience | 11.67B |